Logo image of INZY

INOZYME PHARMA INC (INZY) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INZY - US45790W1080 - Common Stock

4 USD
+0.01 (+0.25%)
Last: 6/30/2025, 8:00:02 PM
3.99 USD
-0.01 (-0.25%)
After Hours: 6/30/2025, 8:00:02 PM
Fundamental Rating

1

Overall INZY gets a fundamental rating of 1 out of 10. We evaluated INZY against 529 industry peers in the Biotechnology industry. Both the profitability and financial health of INZY have multiple concerns. INZY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year INZY has reported negative net income.
  • INZY had a negative operating cash flow in the past year.
  • In the past 5 years INZY always reported negative net income.
  • INZY had a negative operating cash flow in each of the past 5 years.
INZY Yearly Net Income VS EBIT VS OCF VS FCFINZY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of INZY (-112.14%) is worse than 78.83% of its industry peers.
  • With a Return On Equity value of -335.61%, INZY is not doing good in the industry: 73.31% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -112.14%
ROE -335.61%
ROIC N/A
ROA(3y)-55.48%
ROA(5y)-49.12%
ROE(3y)-94.58%
ROE(5y)-74.24%
ROIC(3y)N/A
ROIC(5y)N/A
INZY Yearly ROA, ROE, ROICINZY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for INZY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INZY Yearly Profit, Operating, Gross MarginsINZY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

  • INZY has more shares outstanding than it did 1 year ago.
  • INZY has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, INZY has a worse debt to assets ratio.
INZY Yearly Shares OutstandingINZY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
INZY Yearly Total Debt VS Total AssetsINZY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -6.69, we must say that INZY is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -6.69, INZY is not doing good in the industry: 65.66% of the companies in the same industry are doing better.
  • INZY has a Debt/Equity ratio of 0.65. This is a neutral value indicating INZY is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.65, INZY is doing worse than 74.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z -6.69
ROIC/WACCN/A
WACCN/A
INZY Yearly LT Debt VS Equity VS FCFINZY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • INZY has a Current Ratio of 2.19. This indicates that INZY is financially healthy and has no problem in meeting its short term obligations.
  • INZY has a worse Current ratio (2.19) than 73.13% of its industry peers.
  • INZY has a Quick Ratio of 2.19. This indicates that INZY is financially healthy and has no problem in meeting its short term obligations.
  • INZY has a Quick ratio of 2.19. This is in the lower half of the industry: INZY underperforms 71.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
INZY Yearly Current Assets VS Current LiabilitesINZY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

  • INZY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.44%.
EPS 1Y (TTM)-24.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.96% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.62%
EPS Next 2Y12.98%
EPS Next 3Y14.64%
EPS Next 5Y16.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INZY Yearly Revenue VS EstimatesINZY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
INZY Yearly EPS VS EstimatesINZY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • INZY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year INZY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INZY Price Earnings VS Forward Price EarningsINZY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INZY Per share dataINZY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INZY's earnings are expected to grow with 14.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.98%
EPS Next 3Y14.64%

More info and screens

0

5. Dividend

5.1 Amount

  • INZY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOZYME PHARMA INC

NASDAQ:INZY (6/30/2025, 8:00:02 PM)

After market: 3.99 -0.01 (-0.25%)

4

+0.01 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14
Earnings (Next)08-04
Inst Owners95.96%
Inst Owner Change0%
Ins Owners0.13%
Ins Owner Change0%
Market Cap258.24M
Revenue(TTM)N/A
Net Income(TTM)-106.72M
Analysts72.31
Price Target6.85 (71.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.46%
Min EPS beat(2)-5.86%
Max EPS beat(2)0.94%
EPS beat(4)2
Avg EPS beat(4)-0.85%
Min EPS beat(4)-10.77%
Max EPS beat(4)12.28%
EPS beat(8)4
Avg EPS beat(8)2.8%
EPS beat(12)8
Avg EPS beat(12)6.64%
EPS beat(16)11
Avg EPS beat(16)5.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50.26%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-3.31%
EPS NY rev (1m)-3.7%
EPS NY rev (3m)-4.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.12
P/tB 8.12
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -112.14%
ROE -335.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.48%
ROA(5y)-49.12%
ROE(3y)-94.58%
ROE(5y)-74.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -6.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)33.18%
Cap/Depr(5y)83.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.79%
EPS Next Y9.62%
EPS Next 2Y12.98%
EPS Next 3Y14.64%
EPS Next 5Y16.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.28%
OCF growth 3YN/A
OCF growth 5YN/A

INOZYME PHARMA INC / INZY FAQ

What is the ChartMill fundamental rating of INOZYME PHARMA INC (INZY) stock?

ChartMill assigns a fundamental rating of 1 / 10 to INZY.


Can you provide the valuation status for INOZYME PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to INOZYME PHARMA INC (INZY). This can be considered as Overvalued.


How profitable is INOZYME PHARMA INC (INZY) stock?

INOZYME PHARMA INC (INZY) has a profitability rating of 0 / 10.